Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS)
ARDS, which is characterized by hypoxemic respiratory failure and inflammatory injury to the lungs, has a mortality rate of 30% to 40%. Balasubramanian Venkatesh, MD, of the George Institute for Global Health joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the effects of inhaled sedation with sevoflurane for patients with moderate to severe ARDS. Related Content: Sevoflurane Sedation in Acute Respiratory Distress Syndrome Inhaled Sedation in Acute Respiratory Distress Syndrome
Publisher
Healthy Dialogue
Link
edhub.ama-assn.org/jn-learning/audio-player/10.1001/jama.2025.3350
Published
March 18, 2025
Duration
18 min
Format
Podcast
Category
Lifestyle · Medicine
Source
RSS feed
Host
JAMA Network
Healthy Dialogue
@healthydialogue
#inhaledsedation #sevoflurane #acuterespiratorydistress #medicine
